Alnylam (ALNY) is a $5.1B company and Benitec Biopharma (BTEBY, BNIKF) is a $120M company. Both are biothech companies working in the field of RNAi (RiboNucleic Acid Interference). Both have access to a wide patent estate: Alnylam’s estate covering Small Interfering RNA (siRNA) and Benitec’s estate covering DNA Directed RNAi (ddRNAi and shRNA).

In theory they are competitors, each looking to silence genes which produce harmful levels of proteins. However, in reality this competition has not been manifest. Alnylam has concentrated its pipeline efforts primarily on rare … Read more